Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 2 of 6

  1. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  2. GN41791

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 other active

    1 trial

  3. GO29431

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  4. GO29527

    Hoffmann-La Roche

    Non−Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  5. GO39942

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  6. GO40241

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. GO41717

    Hoffmann-La Roche

    Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  8. GO41767

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  9. GO41854

    Hoffmann-La Roche

    Non−small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. GO41944

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  11. GO42909

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  12. GO43104

    Hoffmann-La Roche

    Small-Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  13. GO45006

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 other active

    1 trial

  14. GR40549

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  15. Gantenerumab

    Hoffmann-La Roche

    Alzheimer Disease

    phase 3 small molecule terminated

    1 trial

  16. Herceptin

    Hoffmann-La Roche

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  17. ML42502

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  18. MN39158

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  19. MN39159

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  20. MN45053

    Hoffmann-La Roche

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. MN45053

    Hoffmann-La Roche

    Neurological Disease

    phase 3 small molecule active

    1 trial

  22. MO29406

    Hoffmann-La Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  23. MO29872

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  24. MO40598

    Hoffmann-La Roche

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  25. MO41552

    Hoffmann-La Roche

    Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

    phase 3 small molecule active

    1 trial

  26. MO41787

    Hoffmann-La Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

  27. MO43110

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  28. MO43110

    Hoffmann-La Roche

    Early Breast Cancer

    phase 3 small molecule completed

    1 trial

  29. MR45625

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  30. Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    NA

    phase 3 small molecule active

    1 trial

  31. Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis, Primary Progressive

    phase 3 small molecule active

    1 trial

  32. Ocrelizumab IV

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  33. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  34. PDS Implant with Ranibizumab 100 mg/mL

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  35. PRM-151 (Zinpentraxin Alfa)

    Hoffmann-La Roche

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule terminated

    1 trial

  36. Pegylated Interferon Alfa-2a

    Hoffmann-La Roche

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  37. Placebo

    Hoffmann-La Roche

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  38. Placebo

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  39. RO5541267

    Hoffmann-La Roche

    Cohort A: • Metastatic non-small cell lung carcinoma (mNSCLC) • Extensive-stage small-cell lung carcinoma (ES-SCLC) • Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: • Resected Stage IIB-IIIB (early-stage; per the UICC/AJCC staging system, 8th edition) non-small cell lung carcinoma (NSCLC)

    phase 3 small molecule active

    1 trial

  40. RO7046015, Placebo Prasinezumab

    Hoffmann-La Roche

    Early-Stage Parkinson’s Disease (PD)

    phase 3 small molecule active

    1 trial

  41. RO7239361

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  42. RO7790121 Placebo, RO7790121

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  43. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  44. RO7790121, RO7790121 Placebo

    Hoffmann-La Roche

    Moderately to Severely Active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  45. Ranibizumab

    Hoffmann-La Roche

    Neovascular Age-related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  46. Satralizumab

    Hoffmann-La Roche

    Neuromyelitis Optica (NMO)

    phase 3 small molecule completed

    1 trial

  47. Satralizumab

    Hoffmann-La Roche

    NMDAR Autoimmune Encephalitis

    phase 3 small molecule active

    1 trial

  48. Satralizumab, Satralizumab

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder (NMOSD)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.